

SYSTEMATIC REVIEW AND META-ANALYSIS

Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

Giacomo Tini , MD*; Edoardo Bertero, MD*; Alessio Signori, PhD; Maria Pia Sormani, MP, PhD; Christoph Maack , MD; Rudolf A. De Boer, MD, PhD; Marco Canepa , MD, PhD; Pietro Ameri , MD, PhD

BACKGROUND: The burden of cancer in heart failure with reduced ejection fraction is apparently growing. Randomized controlled trials (RCTs) may help understanding this observation, since they span decades of heart failure treatment.

METHODS AND RESULTS: We assessed cancer, cardiovascular, and total mortality in phase 3 heart failure RCTs involving $\geq 90\%$ individuals with left ventricular ejection fraction $< 45\%$, who were not acutely decompensated and did not represent specific patient subsets. The pooled odds ratios (ORs) of each type of death for the control and treatment arms were calculated using a random-effects model. Temporal trends and the impact of patient and RCT characteristics on mortality outcomes were evaluated by meta-regression analysis. Cancer mortality was reported for 15 (25%) of 61 RCTs, including 33 709 subjects, and accounted for 6% to 14% of all deaths and 17% to 67% of noncardiovascular deaths. Cancer mortality rate was 0.58 (95% CI, 0.46–0.71) per 100 patient-years without temporal trend ($P=0.35$). Cardiovascular ($P=0.001$) and total ($P=0.001$) mortality rates instead decreased over time. Moreover, cancer mortality was not influenced by treatment (OR, 1.08; 95% CI, 0.92–1.28), unlike cardiovascular (OR, 0.88; 95% CI, 0.79–0.98) and all-cause (OR, 0.91; 95% CI, 0.84–0.99) mortality. Meta-regression did not reveal significant sources of heterogeneity. Possible reasons for excluding patients with malignancy overlapped among RCTs with and without published cancer mortality, and malignancy was an exclusion criterion only for 4 (8.7%) of the RCTs not reporting cancer mortality.

CONCLUSIONS: Cancer is a major, yet overlooked cause of noncardiovascular death in heart failure with reduced ejection fraction, which has become more prominent with cardiovascular mortality decline.

Key Words: cancer ■ comorbidities ■ heart failure ■ mortality

In the past years, analyses of community-based cohorts in the United States,^{1,2} Europe,³ and Japan^{4,5} highlighted a higher frequency of newly diagnosed cancer in subjects with heart failure (HF), as compared with those without HF. Although residual confounding cannot be excluded, these studies indicated an increased incidence of cancer in patients with HF, even after taking into account shared risk factors and cardiovascular medications. Furthermore, the higher rate of cancer diagnosis in individuals with HF did not appear

to result from a surveillance bias, that is, a higher likelihood of tumor detection secondary to increased medical attention for subjects with HF.³ Mortality of patients with HF and cancer was also reported to be increased.^{1–5} The association with cancer was primarily observed in HF with reduced left ventricular ejection fraction (HFrEF) and was consistent for most common cancer types.^{1,3} This epidemiologic evidence is strengthened by preclinical data indicating that the failing heart may promote neoplastic development and

Correspondence to: Pietro Ameri, MD, PhD, Cardiovascular Diseases Unit, IRCCS Ospedale Policlinico San Martino & Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6 - 16132 Genova, Italy. E-mail: pietroameri@unige.it

Supplementary Materials for this article are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.016309>

*Dr Tini and Dr Bertero contributed equally to this work and are co-first authors.

For Sources of Funding and Disclosures, see page 11.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- When evaluated, cancer mortality accounted for 6% to 14% of deaths in randomized controlled trials of heart failure with reduced ejection fraction and was not affected by treatments, which instead decreased cardiovascular mortality.
- However, cancer mortality was not assessed in the majority of heart failure with reduced ejection fraction randomized controlled trials.

What Are the Clinical Implications?

- Cancer is a major, yet overlooked cause of noncardiovascular death in heart failure with reduced ejection fraction, which has become more prominent with cardiovascular mortality decline.

Nonstandard Abbreviations and Acronyms

HF	heart failure
HFpEF	heart failure with preserved left ventricular ejection fraction
HFrEF	heart failure with reduced left ventricular ejection fraction
OR	odds ratios
RCTs	randomized controlled trials

progression.⁶ Nonetheless, one investigation based on the Physicians' Health Studies I and II population did not observe any relationship between HF and incident cancer among males.⁷

Clearly, recognition of the potential relation of HFrEF with cancer is growing, but understanding of the interconnection between these 2 entities remains limited.⁸

It is possible that cancer has gained importance in HFrEF because of the changes that occurred in the natural history of this syndrome over time. Advances in pharmacologic and device treatment have led to a significant decline in HF-related cardiovascular mortality, to the extent that overall mortality has also decreased.⁹ By contrast, HFrEF therapies do not affect noncardiovascular disorders, which have therefore progressively become more prominent.^{9–11} This may also be the case with cancer. Indeed, cancer has been recently pinpointed as a major cause of noncardiovascular death in contemporary HFrEF populations.^{9,11,12}

To better describe the relevance of cancer in HFrEF throughout the last decades, we systematically assessed cancer mortality in phase 3 randomized controlled trials (RCTs) and investigated whether it has

been influenced by HFrEF therapies as compared with cardiovascular and total mortality.

METHODS

The authors declare that all supporting data are available within the article and its online supplementary files.

Search Strategy

We systematically searched the MEDLINE, Embase, Scopus, and Cochrane Library databases for phase 3 RCTs in HFrEF using the search strings “heart failure,” “congestive heart failure,” and “randomized controlled trial.” Moreover, we thoroughly screened the bibliographies of original research articles, guidelines, reviews, and meta-analyses to identify additional eligible studies. The search was limited to English language peer-reviewed publications and is updated to April 30, 2019.

Inclusion and Exclusion Criteria

We focused on HFrEF because this type of HF has primarily been the object of RCTs as well as of the investigations about comorbid cancer.^{1,3,8} After selecting phase 3 RCTs involving individuals with left ventricular ejection fraction <45%, we excluded those that included >10% of patients with HF with preserved left ventricular ejection fraction (HFpEF), enrolled subjects with or recently discharged after acutely decompensated HF, were not broadly representative of the HFrEF population (ie, investigating only specific subsets of patients), or did not have sufficient information about mortality. Two investigators (G.T., E.B.) independently reviewed the retrieved articles and collected information regarding number, sex and age of participants, follow-up duration, HF therapy including implantable cardioverter defibrillator and cardiac resynchronization therapy with defibrillator capacity, enrollment criteria with special attention to those regarding malignancy, and cause-specific and total mortality.

Data Synthesis and Statistical Analysis

Mortality rates were calculated per 100 patient-years with 95% CI. The odds ratios (ORs) of cancer, cardiovascular, and all-cause death were obtained from the number of events and the total number of patients in the control and treatment arms. The ORs were then pooled together using the random-effects model based on the method of DerSimonian and Laird. The estimate of heterogeneity was derived from the Mantel-Haenszel model and was reported using the I-square coefficient. Since the number of cancer deaths was low in several RCTs, the Mantel-Haenszel exact test on log OR was also used to evaluate the effect of treatment on cancer mortality. A random-effects




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the systematic search and selection process.

CV indicates cardiovascular; HF, heart failure; HFpEF, heart failure with preserved left ventricular ejection fraction; HFrEF, heart failure with reduced left ventricular ejection fraction; and RCTs, randomized controlled trials.

meta-regression analysis, with the between-studies variance (τ^2) estimated by residual maximum likelihood, was performed to assess possible temporal trends of the mortality rates and to determine whether the following patient and trial characteristics had an impact on mortality outcomes: age and sex of recruited subjects; length of follow-up; number of disease-modifying drug classes in the background

therapy (0–3: beta-blockers; inhibitors of the renin-angiotensin system including aliskiren, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists); and proportion of patients with implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator capacity. Statistical analysis was done using Stata (v.14; StataCorp, College Station, TX).

Table 1. HFREF RCTs With Published Cancer Mortality

Trial name and period	N (males) and age of patients	Follow-up y	Tested therapy Background disease-modifying therapy	All-cause mortality N n/100 pts/y (95% CI)	Cardiovascular mortality N n/100 pts/y (95% CI)	Cancer mortality N n/100 pts/y (95% CI)	Non cardiovascular noncancer mortality N n/100 pts/y (95% CI)	Non cardiovascular deaths attributable to cancer
CONSENSUS 1995–1996 ¹³	253 (178) 70 y	1	Enalapril vs placebo	118	117	0	1	0%
			BB: 3% MRA: 53%	46.6 (40.6–52.8)	46.3 (40.2–52.4)	0	0.4 (0.1–2.2)	
V-HeFT II 1986–1990 ¹⁴	804 (804) 60.6 y	2.5	Enalapril vs hydralazine-isosorbide	285	249	18	18	0%
			ACEI: 61%	14.2 (12.7–15.8)	12.4 (11–13.9)	0.9 (0.6–1.4)	0.9 (0.6–1.4)	
GESICA 1989–1993 ¹⁵	516 (417) 58.8 y	1.1	Amiodarone vs standard therapy	193	185	2	6	25%
			ACEI: 90%	34 (30.2–38)	32.6 (28.9–36.6)	0.4 (0.1–1.3)	1.1 (0.5–2.3)	
CABG Patch 1993–1997 ^{16,74}	900 (759) 63.5 y	2.7	ICD vs standard therapy	198	163	13	22	37.1%
			BB: 21%	8.2 (7.1–9.3)	6.7 (5.8–7.8)	0.5 (0.3–0.9)	0.9 (0.6–1.4)	
			ACEI: 54%					
			ICD: 50%					
DEFINITE 1998–2003 ¹⁷	458 (326) 58.3 y	2.4	ICD vs standard therapy	68	43	10	15	66.7%
			BB: 86%	6.2 (4.9–7.8)	3.9 (2.9–5.2)	0.9 (0.5–1.7)	1.4 (0.8–2.2)	
			ACEI: 86 %					
			ARB: 11%					
CHARM-Alternative 1999–2003 ^{18,75}	2028 (1382) 66.6 y	2.8	Candesartan vs placebo	561	471	43	47	47.8%
			BB: 55%	9.9 (9.1–10.7)	8.3 (7.6–9.0)	0.8 (0.6–1)	0.8 (0.6–1.1)	
			MRA: 24%					
			ICD: 3%					
CHARM-Added 1999–2003 ^{19,75}	2548 (2006) 64.1 y	3.4	Candesartan vs placebo	789	649	54	86	38.6%
			BB: 56%	9.1 (8.5–9.7)	7.5 (7–8.1)	0.6 (0.5–0.8)	1 (0.8–1.2)	
			ACEI: 100%					
			MRA: 17%					
AF-CHF 2001–2007 ²⁰	1376 (1122) 67 y	3.1	Rhythm control vs rate control	445	357	34	54	38.6%
			BB: 79%	10.4 (9.6–11.4)	8.4 (7.6–9.2)	0.8 (0.6–1.1)	1.3 (1–1.7)	
			ACEI: 86%					
			ARB: 11%					
			MRA: 45%					
			ICD: 7%					

(Continued)

Table 1. Continued

Trial name and period	N (males) and age of patients	Follow-up y	Tested therapy Background disease-modifying therapy	All-cause mortality N n/100 pts/y (95% CI)	Cardiovascular mortality N n/100 pts/y (95% CI)	Cancer mortality n/100 pts/y (95% CI)	Non cardiovascular noncancer mortality N n/100 pts/y (95% CI)	Non cardiovascular deaths attributable to cancer
GISSI-HF 2002–2008 ²¹	6975 (6459) 67 y	3.9	n-3 PUFA vs standard therapy	1969	1477	219	273	44.5%
			BB: 66%	7.2 (6.9–7.5)	5.4 (5.1–5.7)	0.8 (0.7–0.9)	1 (0.9–1.1)	
			ACEi: 77%					
			ARB: 19%					
			MRA: 39%					
ICD: 7%								
STICH 2002–2010 ^{22,76}	1212 (1064) 60 y	4.7	CABG vs standard therapy	462	351	35	76	31.5%
			BB: 86%	8.1 (7.4–8.9)	6.2 (5.6–6.8)	0.6 (0.4–0.9)	1.3 (1.1–1.7)	
			ACEi: 82%					
			ARB: 9.5%					
			MRA: 46%					
CORONA 2003–2007 ²³	5001 (3821) 73 y	2.7	Rosuvastatin vs placebo	1487	975	102	410	19.9%
			BB: 75%	11 (10.5–11.5)	7.2 (6.8–7.7)	0.8 (0.6–0.9)	3 (2.8–3.3)	
			ACEi/ARB: 92%					
			MRA: 39%					
			ICD: 3%					
REVERSE 2004–2006 ²⁴	610 (479) 62.4 y	1	CRT vs standard therapy	12	6	1	5	16.7%
			BB: 95%	2 (1.1–3.4)	1 (0.5–2.1)	0.2 (0.1–0.9)	0.8 (0.4–1.9)	
			ACEi: 79%					
			ARB: 21%					
			ICD: 84%					
MADIT-CRT 2004–2008 ^{25,77}	1820 (1367) 64.5 y	4	CRT-D vs ICD	169	108	19	42	31.1%
			BB: 92%	2.3 (2–2.7)	1.5 (1.2–1.8)	0.3 (0.2–0.4)	0.6 (0.4–0.8)	
			ACEi: 74%					
			ARB: 20%					
			MRA: 30%					
ICD: 50%								
ECHO-CRT 2008–2013 ²⁶	809 (665) 58 y	1.6	CRT vs standard therapy	71	48	5	18	21.7%
			BB: 97%	5.5 (4.4–6.9)	3.7 (2.8–4.9)	0.4 (0.2–0.9)	1.4 (0.9–2.2)	
			ACEi/ARB: 95%					
			MRA: 60%					
			ICD: 50%					

(Continued)

Table 1. Continued

Trial name and period	N (males) and age of patients	Follow-up y	Tested therapy Background disease-modifying therapy	All-cause mortality N n/100 pts/y (95% CI)	Cardiovascular mortality N n/100 pts/y (95% CI)	Cancer mortality n/100 pts/y (95% CI)	Non cardiovascular noncancer mortality N n/100 pts/y (95% CI)	Non cardiovascular deaths attributable to cancer
PARADIGM-HF 2009–2014 ^{27,78}	8399 (6567) 63.8 y	2.3	ARNI vs ACEI BB: 93% ACEI: 77.8% ARB: 22.6% MRA: 56% ICD: 15%	1546 8 (7.6–8.4)	1251 6.5 (6.1–6.8)	82 0.4 (0.3–0.5)	213 1.1 (1–1.3)	27.8%

CORONA included only >60 year-old patients.

Age and follow-up duration are mean or median, as published. When presented in months, follow-up duration was converted into years by dividing by 12.

ACEI indicates angiotensin-converting enzyme inhibitor; AF-CHF, atrial fibrillation and congestive heart failure; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta-blocker; CABG, coronary artery bypass graft; CHARM-Added, candesartan in heart failure assessment of reduction in mortality and morbidity-added; CHARM-Alternative, candesartan in heart failure assessment of reduction in mortality and morbidity-alternative; CONSENSUS, cooperative north scandinavian enalapril survival study; CORONA, controlled rosuvastatin multinational trial in heart failure; CRT(-D), cardiac resynchronization therapy (and ICD); DEFINITE, defibrillators in non-ischemic cardiomyopathy treatment evaluation; ECHO-CRT, echocardiography guided cardiac resynchronization therapy; GESICA, grupo de estudio de la sobrecarga en la insuficiencia cardiaca en Argentina GISSI-HF, gruppo Italiano per lo studio della sopravvivenza nell'insufficienza cardiaca heart failure; HFrEF, heart failure with reduced left ventricular ejection fraction; ICD, implanted cardioverter defibrillator; MADIT-CRT, multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy; MRA, mineral receptor antagonist; PARADIGM-HF, prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial; PUFA, polyunsaturated fatty acids; RCTs, randomized controlled trials; REVERSE, resynchronization reverses remodeling in systolic left ventricular dysfunction; STICH, surgical treatment for ischemic heart failure; and V-HeFT II, vasodilator-heart failure trial II.

RESULTS

A total of 61 HFrEF RCTs were included in the analysis^{13–73}; Figure 1 shows the flow diagram of the selection process.

Cancer mortality was reported for 15 (25%) RCTs.^{13–27,74–78} These studies covered 29 years, from 1985 to 2014, and involved a total of 33 709 subjects aged between 58 and 70 years, with the exception of CORONA²³ that included ≥60-year-old patients and, thereby, consisted of an older cohort (Table 1; risk of bias is summarized in Table S1). The number of participants, as well as the complexity of HFrEF treatment, progressively increased from the earliest to the latest RCTs. Duration of follow-up ranged from 1 to 4.7 years (Table 1). The proportion of patients with cancer at the enrollment was available for 3 RCTs and always small: CHARM Alternative¹⁸ (134 patients, 6.6% of total), CHARM Added¹⁹ (153 patients, 6%), and GISSI-HF²¹ (256 patients, 3.7%).

Except for 2 of the earliest RCTs with published information about cancer mortality (CONSENSUS¹³ and GESICA¹⁵), cancer accounted for 6% to 14% of all deaths and 17% to 67% of noncardiovascular deaths (Table 1). The inferred mortality rate was 0.58 (95% CI, 0.46–0.71) per 100 patient-years (I2 for heterogeneity, 83.4%) and did not have a clear temporal trend ($P=0.35$; Figure 2). The cancer mortality rates for the population of corresponding age in the United States, provided in Table S2, were in general lower than in RCTs before the 2000s and then comparable. Similar to cancer mortality, no significant trend was noted for noncardiovascular noncancer mortality rates ($P=0.24$; Table 1). Conversely, cardiovascular ($P=0.001$) and total ($P=0.001$) mortality rates decreased over time (Table 1 and Figure 2). Furthermore, HFrEF therapies did not modify cancer mortality (OR, 1.08; 95% CI, 0.92–1.28; Figure 3A), but significantly diminished cardiovascular (OR, 0.88; 95% CI, 0.79–0.98; Figure 3B) and all-cause (OR, 0.91; 95% CI, 0.84–0.99; Figure 3C) mortality. The Mantel-Haenszel exact test for cancer mortality yielded similar results (OR, 1.09; 95% CI, 0.92–1.27). None of the patient or RCT characteristics taken into consideration reduced heterogeneity in the meta-regression analysis of treatment effect (Table S3). However, part of the heterogeneity for the cardiovascular death outcome was imputable to the ECHO-CRT and V-HeFT-II studies, since removing these 2 RCTs decreased heterogeneity from 64.5% to 54.4% and 57.9%, respectively. The leave-one-out approach with the other RCTs did not substantially modify the heterogeneity for cardiovascular death.

Information about cancer mortality was not given for 46 (75%) RCTs.^{28–73,79–91} The main features of these RCTs are presented in Table S4. Of note, only 4 of these studies^{43,44,63,72} (8.7% of the RCTs without




Figure 2. Cancer and CV mortality in HFrEF RCTs with cancer mortality data available.

AF-CHF indicates atrial fibrillation and congestive heart failure; CABG, coronary artery bypass graft; CHARM-Added, candesartan in heart failure assessment of reduction in mortality and morbidity-added; CHARM-Alternative, candesartan in heart failure assessment of reduction in mortality and morbidity-alternative; CONSENSUS, cooperative north scandinavian enalapril survival study; CORONA, controlled rosuvastatin multinational trial in heart failure; CV, cardiovascular; DEFINITE, defibrillators in non-ischemic cardiomyopathy treatment evaluation; ECHO-CRT, echocardiography guided cardiac resynchronization therapy; GESICA, grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina; GISSI-HF, gruppo Italiano per lo studio della sopravvivenza nell'insufficienza cardiaca heart failure; HFrEF, heart failure with reduced left ventricular ejection fraction; MADIT-CRT, multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy; PARADIGM-HF, prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial; RCTs, randomized controlled trials; REVERSE, resynchronization reverses remodeling in systolic left ventricular dysfunction; STICH, surgical treatment for ischemic heart failure; and V-HeFT II, vasodilator-heart failure trial II.

published cancer mortality) formally excluded patients with current and/or prior malignancy (Figure 4 and Table S5). Most RCTs did not enroll individuals who might have had cancer, based on limited life expectancy (12 RCTs[†]; 26% of those without data on cancer mortality), a predicted survival below a specific cutoff

between 6 months and 5 years (11 RCTs[§]; 24%), the presence of concomitant “major noncardiac diseases” (4 RCTs^{41,51,66,69} 9%), or the assumption that complete follow-up would not be feasible (3 RCTs^{49,60,65} 6.5%). In 12 studies,[¶] (26%) there was not even indirect indication that patients with cancer could not be recruited

[†]References 13, 29, 32, 35, 36, 38–40, 42, 47, 48, 59.

[§]References 28, 33, 46, 52, 54–56, 58, 64, 71, 73.

[¶]References 31, 34, 37, 45, 50, 53, 57, 61, 62, 67, 68, 70




Figure 3. Pooled OR for cancer, CV, and total mortality in HFrEF RCTs with published information about cancer mortality.

AF-CHF indicates atrial fibrillation and congestive heart failure; CABG, coronary artery bypass graft; CHARM-Added, candesartan in heart failure assessment of reduction in mortality and morbidity-added; CHARM-Alternative, candesartan in heart failure assessment of reduction in mortality and morbidity-alternative; CONSENSUS, cooperative north scandinavian enalapril survival study; CORONA, controlled rosuvastatin multinational trial in heart failure; CRT-(D), cardiac resynchronization therapy (and ICD); CV, cardiovascular; DEFINITE, defibrillators in non-ischemic cardiomyopathy treatment evaluation; ECHO-CRT, echocardiography guided cardiac resynchronization therapy; GESICA, grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina; GISSI-HF, gruppo Italiano per lo studio della sopravvivenza nell'insufficienza cardiaca heart failure; HFrEF, heart failure with reduced left ventricular ejection fraction; MADIT-CRT, multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy; PARADIGM-HF, prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial; RCTs, randomized controlled trials; REVERSE, resynchronization reverses remodeling in systolic left ventricular dysfunction; STICH, surgical treatment for ischemic heart failure; and V-HeFT II, vasodilator-heart failure trial II.

(Figure 4 and Table S5). Strikingly, very similar exclusion criteria were applied in the RCTs that instead reported cancer mortality, with a comorbidity expected to shorten life expectancy to less than the duration of follow-up or a variable amount of time being the most common reason to preclude the participation of patients with active cancer (Figure 4 and Table 2). In CONSENSUS¹³ and DEFINITE,¹⁷ noncardiac diseases leading to exclusion were explicitly listed, and cancer was not mentioned (Table 2).

DISCUSSION

There is increasing attention toward cancer in HFrEF. Contemporary registries suggest that at minimum 1 in 10 patients with HFrEF also has a malignant tumor at the first observation^{11,92,93} or is diagnosed with and dies from cancer during follow-up.^{1-5,11,12,92,93} In fact, the risk of malignancy may be even higher in subjects with than without HFrEF.¹⁻⁴

Since RCTs provide robust and high-quality data, we systematically reviewed these studies to better define the burden of cancer in HFrEF. In the 15 HFrEF RCTs with published cancer mortality, the proportion of deaths ascribed to malignancy was not negligible, being 6% to 7% and peaking at over 14%. Up to 67% of noncardiovascular deaths were attributable to cancer. These results are consistent with those of recent investigations assessing cancer in HF out of RCTs. By reviewing the electronic health records from a representative sample of the UK population, Conrad and colleagues showed that cancer caused 15% of deaths within 1 year from HF diagnosis in 2013.¹¹ Of about 1800 patients with HFrEF followed at one HF clinic in Spain and >2000 from another single center in Japan,

15% and 16%, respectively, died from cancer.^{92,93} Thus, our work confirms that cancer is a relevant cause of death in HFrEF, by integrating retrospective analyses of real-world cohorts with data from prospective RCTs, which have been extracted and examined here for the first time.

While there was no consistent trend in cancer mortality throughout HFrEF RCTs, cardiovascular and all-cause mortality decreased. This reduction has already been described for HFrEF RCTs in general^{9,94} and in population studies,^{9,11,12} and is explained by the sequential implementation of drugs and devices halting HF progression and death. In fact, the decline in cardiovascular and overall mortality in our analysis was driven by the 3 oldest RCTs,¹³⁻¹⁵ in which HF-specific therapy was simpler than in the following ones. By contrast, cancer mortality was not influenced by treatment, in line with the epidemiologic evidence that neurohormonal inhibitors do not substantially affect the risk of dying from malignant tumors.⁹⁵ Hence, the emerging issue of cancer in HFrEF may be, at least in part, the consequence of curtailed cardiovascular death by virtue of therapeutic advances. This paradigm has also been proposed for other comorbidities that nowadays compete with HFrEF per se in dictating prognosis more than in the past and has prompted questions about the appropriateness of some treatment choices.^{10,17} It must be acknowledged that this interpretation of the results is speculative and needs to be verified. Nevertheless, the data presented here corroborate the debate and emphasize that cancer is a noncardiovascular disease complicating HFrEF, which deserves careful consideration.

Interestingly, a specular trend has been shown for cardiovascular mortality among oncologic patients,




Figure 4. Potential reasons for exclusion of patients with malignancy from HFrEF RCTs.

Note the overlap of criteria between trials for which cancer mortality was or was not reported. *Cancer not considered* means that cancer was not a direct or indirect cause of exclusion.

where cardiovascular deaths have become more frequent with the improvement of cancer prognosis.⁹⁶ Thus, the reciprocal impact of the evolving epidemiology of cardiovascular disease and cancer must be borne in mind when addressing their interrelation.

Three RCTs reported the percentage of patients having cancer at baseline, which was 3.7% to 6.6%^{18,19,21} and lower than the ones found in the general population. Among subjects with incident HF in the United Kingdom between 2011 and 2013, 29% also had a history of cancer.¹¹ In the United States, comorbid nonmetastatic cancer was recorded for 11% of all the admissions between 2003 and 2015 with a primary discharge diagnosis of HF.^{92,93} This discrepancy may depend on the inaccurate definition of HF in population studies, with no distinction between HFrEF and HFpEF. It is also likely that oncologic patients were somehow excluded from RCTs, but not from registries. However, it should also be noted that the representation of subjects with malignancy in HFrEF RCTs is largely unknown. Only 4 RCTs^{43,44,63,72} explicitly excluded these patients. In the great majority of RCTs, participation was precluded to individuals with a concomitant noncardiovascular condition, which would jeopardize follow-up or substantially decrease life expectancy according to the recruiting investigators. Obviously, such conditions could have been, but were not necessarily limited to, cancer. Therefore, it is conceivable that a number of individuals were enrolled in HFrEF RCTs in spite of having malignant tumors, although apparently cured or deemed indolent.

The majority of HFrEF RCTs also lack information about how many patients died from cancer. Modes of death were reported as cardiovascular or noncardiovascular, without further distinction of the noncardiovascular causes of death. This methodologic limitation generates a gap in knowledge about cancer in HFrEF and has negative implications for clinical practice. Since guidance may not be derived from RCTs, the management of patients with cancer in addition to HFrEF remains empirical and based on personal experience, when evidence-based data are instead warranted given the challenges portended by the co-occurrence of cancer and HF.⁹⁷ We advocate for future RCTs better describing and adjudicating noncardiovascular events and mortality, including incident and fatal cancer.

From a conceptual standpoint, the results presented here lend support to the statement that the discipline of cardio-oncology should broaden goals and perspectives. The interfaces between cancer and HF and other cardiovascular disorders are manifold and not limited to the side effects of antitumor therapies. Basic and clinical science efforts are awaited to dissect these multiple levels of interaction

Table 2. Potential Reasons for Exclusion of Patients With Malignancy From HFrEF RCTs With Cancer Mortality Data Available

	Exclusion Criteria Possibly Regarding Patients With Cancer
CONSENSUS ¹³	<i>Cancer not a direct or indirect reason for exclusion</i>
V-HeFT II ⁴	"Diseases likely to limit life expectancy"
GESICA ¹⁵	"Concomitant serious disease"
CABG Patch ^{16,74}	"A noncardiovascular condition with expected survival of less than two years"
DEFINITE ¹⁷	<i>Cancer not a direct or indirect reason for exclusion</i>
CHARM Alternative ^{18,75}	"Presence of any noncardiac disease (eg, cancer) that is likely to significantly shorten life expectancy to <2 years."
CHARM Added ^{19,75}	"Presence of any noncardiac disease (eg, cancer) that is likely to significantly shorten life expectancy to less than 2 years."
AF-CHF ²⁰	"An estimated life expectancy of less than 1 year"
GISSI-HF ²¹	"Presence of any noncardiac comorbidity (eg, cancer) unlikely to be compatible with a sufficiently long follow-up"
STICH ^{22,76}	"Noncardiac illness with a life expectancy of less than 3 years" "Noncardiac illness imposing substantial operative mortality"
CORONA ²³	"Any other condition that would substantially reduce life expectancy or limit compliance with the protocol"
REVERSE ²⁴	Life expectancy ≤12 months
MADIT-CRT ^{25,77}	"Presence of any disease, other than the subject's cardiac disease, associated with a reduced likelihood of survival for the duration of the trial, eg, cancer, uremia (BUN >70 mg/dL or creatinine >3.0 mg/dL), liver failure, etc"
ECHO-CRT ²⁶	"Have a life expectancy of <6 months. Presence of any disease, other than the subject's cardiac disease associated with a reduced likelihood of survival for the duration of the trial, (eg, cancer)"
PARADIGM-HF ^{27,78}	"Presence of any other disease with a life expectancy of <5 years"

AF-CHF indicates atrial fibrillation and congestive heart failure; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHARM-Added, candesartan in heart failure assessment of reduction in mortality and morbidity-added; CHARM-Alternative, candesartan in heart failure assessment of reduction in mortality and morbidity-alternative; CONSENSUS, cooperative north scandinavian enalapril survival study; CORONA, controlled rosuvastatin multinational trial in heart failure; DEFINITE, defibrillators in non-ischemic cardiomyopathy treatment evaluation; ECHO-CRT, echocardiography guided cardiac resynchronization therapy; GESICA, grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina; GISSI-HF, gruppo Italiano per lo studio della sopravvivenza nell'insufficienza cardiaca heart failure; HFrEF, heart failure with reduced left ventricular ejection fraction; MADIT-CRT, multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy; PARADIGM-HF, prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial; RCTs, randomized controlled trials; REVERSE, resynchronization reverses remodeling in systolic left ventricular dysfunction; STICH, surgical treatment for ischemic heart failure; and V-HeFT II, vasodilator-heart failure trial II.

and provide insights, which may be in turn translated into clinical improvements. Our analysis highlights how the extensive phenotyping offered by RCTs has

been minimally exploited to characterize cancer in HFrEF. In parallel, investigations are needed to understand whether a mechanistic link exists between the 2 conditions.^{95,98,99}

Limitations

This systematic review collected information from RCTs, which were not specifically designed to evaluate cancer mortality in HFrEF. As such, adjudication and proper event description, by default, was of mediocre quality. Second, the competing risk explanation for the increasing relevance of cancer in HFrEF is strongly hampered by the lack of any analysis that directly address it. In this regard, this work should be considered hypothesis-generating. Third, we did not assess the burden of malignancy in HFpEF. However, a recent comprehensive paper examined noncardiovascular death in HFpEF RCTs and found that detailed data were available only for 3 studies.¹⁰⁰ In these RCTs, 30% to 40% of noncardiovascular mortality was attributable to cancer, suggesting that death attributable to malignancy is also noticeable in this setting.

CONCLUSIONS

When assessed, cancer was a primary cause of noncardiovascular death in RCTs in patients with HFrEF, and it was unaffected by HF treatments. However, cancer mortality was often unreported. Given the increasing number of subjects with HF and cancer, restrictive exclusion criteria or inadequate data collection may hinder the appropriate representation of a relevant population in RCTs. A similar observation has been made for RCTs of anticancer therapies, where concomitant cardiovascular disease and especially HF are a common reason for exclusion.¹⁰¹ Upcoming HFrEF RCTs should consider including at least a subset of patients with thorough information about the prevalence, characteristics, and mortality of cancer, as this would allow better positioning of new therapies.

Sources of Funding

Pietro Ameri is supported by the Italian Ministry of Health (Ricerca Corrente 2018–2020 and GR-2018–12365661, Cancer in Heart Failure: characterizing the association with a dual epidemiological and Experimental approach [CHANGE study]); Rudolf A. de Boer is supported by the European Research Council (ERC CoG 818715, Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure [SECRETE-HF]).

ARTICLE INFORMATION

Received February 29, 2020; accepted May 27, 2020.

Affiliations

From the Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy (G.T., M.C., P.A.); Department of Internal Medicine, University of Genova, Italy (G.T., M.C., P.A.); Comprehensive Heart Failure Center (CHFC), University Clinic Würzburg, Würzburg, Germany (E.B., C.M.); Department of Health Sciences, Section of Biostatistics, University of Genova, Italy (A.S., M.P.S.); and Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands (R.A.D.B.).

Disclosures

None.

Supplementary Materials

Tables S1–S5

REFERENCES

- Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, Cerhan JR, Roger VL. Patients with heart failure have an increased risk of incident cancer. *J Am Coll Cardiol*. 2013;62:881–886.
- Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, Cerhan JR, Roger VL. Heart failure after myocardial infarction is associated with increased risk of cancer. *J Am Coll Cardiol*. 2016;68:265–271.
- Banke A, Schou M, Videbaek L, Møller JE, Torp-Pedersen C, Gustafsson F, Dahl JS, Køber L, Hildebrandt PR, Gislason GH. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. *Eur J Heart Fail*. 2016;18:260–266.
- Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, Mochizuki N, Anzai T, Hamasaki T, Kitakaze M. Does the pathophysiology of heart failure prime the incidence of cancer? *Hypertens Res*. 2017;40:831–836.
- Oikawa T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, Sato M, Aoyanagi H, Shiroto T, Sugimura K, et al.; CHART-2 Investigators. Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. *Int J Cardiol*. 2019;290:106–112.
- de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. *Eur J Heart Fail*. 2019;21:1515–1525.
- Selvaraj S, Bhatt DL, Claggett B, Djoussé L, Shah SJ, Chen J, Imran TF, Qazi S, Sesso HD, Gaziano JM, et al. Lack of association between heart failure and incident cancer. *J Am Coll Cardiol*. 2018;71:1501–1510.
- Bertero E, Ameri P, Maack C. Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology. *Card Fail Rev*. 2019;5:106–111.
- Rush CJ, Campbell RT, Jhund PS, Connolly EC, Preiss D, Gardner RS, Petrie MC, McMurray JJV. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. *JACC Heart Fail*. 2015;3:603–614.
- Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, Di Nora C, Cioffi G, Tarantini L, Gavazzi A, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. *Eur J Heart Fail*. 2018;20:1257–1266.
- Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes A-C, Millett ERC, Salimi-Khorshidi G, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. *JAMA Cardiol*. 2019;4:1102–1111.
- Moliner P, Lupón J, de Antonio M, Domingo M, Santiago-Vacas E, Zamora E, Cediel G, Santemas J, Diez-Quevedo C, Troya MI, et al. Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. *Eur J Heart Fail*. 2019;21:1259–1266.
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med*. 1987;316:1429–1435.
- Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*. 1991;325:303–310.

15. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). *Lancet Lond Engl*. 1994;344:493–498.
16. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. *N Engl J Med*. 1997;337:1569–1575.
17. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med*. 2004;350:2151–2158.
18. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Östergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*. 2003;362:772–776.
19. McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. 2003;362:767–771.
20. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JMO, Buxton AE, Camm AJ, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008;358:2667–2677.
21. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;372:1223–1230.
22. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med*. 2011;364:1607–1616.
23. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*. 2007;357:2248–2261.
24. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol*. 2008;52:1834–1843.
25. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med*. 2009;361:1329–1338.
26. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Górcsan J, Gras D, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. *N Engl J Med*. 2013;369:1395–1405.
27. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993–1004.
28. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med*. 1986;314:1547–1552.
29. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*. 1991;325:293–302.
30. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med*. 1992;327:685–691.
31. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Effect of oral milrinone on mortality in severe chronic heart failure. *N Engl J Med*. 1991;325:1468–1475.
32. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation*. 1994;90:1765–1773.
33. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazerri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. *N Engl J Med*. 1995;333:77–82.
34. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med*. 1997;336:525–533.
35. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. *Circulation*. 1997;96:856–863.
36. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med*. 1996;335:1107–1114.
37. Hampton J, van Veldhuisen D, Kleber F, Cowley A, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. *Lancet*. 1997;349:971–977.
38. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. *Lancet*. 1997;349:375–380.
39. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med*. 1996;334:1349–1355.
40. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. *Circulation*. 1999;100:2312–2318.
41. Levine TB, Bernink PJLM, Caspi A, Elkayam U, Geltman EM, Greenberg B, McKenna WJ, Ghali JK, Giles TD, Marmor A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure. *Circulation*. 2000;101:758–764.
42. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snively DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*. 1997;349:747–752.
43. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. *N Engl J Med*. 1998;339:1810–1816.
44. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med*. 1999;341:709–717.
45. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*. 1999;353:9–13.
46. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med*. 2001;344:1659–1667.
47. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau J-L, Schocken D, Anderson SA, DeMets DL. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 Study (Prospective Randomized Amlodipine Survival Evaluation 2). *JACC Heart Fail*. 2013;1:308–314.
48. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*. 2003;362:7–13.
49. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999;353:2001–2007.
50. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet*. 2000;355:1582–1587.
51. Packer M, Krum H, Castaigne A. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001;10:49.

52. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med.* 2001;345:1667–1675.
53. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med.* 2005;352:225–237.
54. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; for the MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail.* 2003;5:659–667.
55. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol.* 2003;42:1454–1459.
56. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med.* 2004;350:2140–2150.
57. Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, et al.; On behalf of the CARMEN investigators and co-ordinators. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-inhibitor Remodelling Mild CHF EvaluationN). *Eur J Heart Fail.* 2004;6:467–475.
58. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med.* 2005;352:1539–1549.
59. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet.* 2009;374:1840–1848.
60. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. *Circulation.* 2005;112:2426–2435.
61. Mortara A, Pinna GD, Johnson P, Maestri R, Capomolla S, La Rovere MT, Ponikowski P, Tavazzi L, Sleight P, on behalf of the HHH Investigators. Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). *Eur J Heart Fail.* 2009;11:312–318.
62. Hare JM, Mangal B, Brown J, Fisher C, Freudenberg R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. *J Am Coll Cardiol.* 2008;51:2301–2309.
63. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moyé LA, Otterstad JE, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. *Lancet.* 2008;371:228–236.
64. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. *J Am Coll Cardiol.* 2010;56:692–699.
65. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, et al.; for the HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA.* 2009;301:1439–1450.
66. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med.* 2010;363:2385–2395.
67. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. *Circ Heart Fail.* 2008;1:9–16.
68. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet.* 2010;376:875–885.
69. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med.* 2010;364:11–21.
70. Hindricks G, Taborisky M, Glikson M, Heinrich U, Schumacher B, Katz A, Brachmann J, Lewalter T, Goette A, Block M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. *Lancet.* 2014;384:583–590.
71. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M, Boll H, Baumann G, Honold M, Koehler K, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure. *Circulation.* 2011;123:1873–1880.
72. Køber L, Thune JJ, Nielsen JC, Haarbø J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. *N Engl J Med.* 2016;375:1221–1230.
73. Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW, de Jong R, Linssen G, Lok DJA, Berge M, et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study: long-term follow-up in optimally treated and stable HF patients. *Eur J Heart Fail.* 2014;16:1241–1248.
74. Bigger JT, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, Steinman RC, Estes NAM. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. *Circulation.* 1999;99:1416–1421.
75. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, Swedberg K, Yusuf S, Granger CB, Michelson EL, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation.* 2004;110:2180–2183.
76. Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, et al. Surgical treatment for ischemic heart failure (STICH) trial: mode of death results. *JACC Heart Fail.* 2013;1:400–408.
77. for the MADIT-CRT Investigators, Perkiomaki JS, Ruwald AC, Kutyla V, Ruwald MH, McNitt S, Polonsky B, Goldstein RE, Haigney MC, et al. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. *EP Eur.* 2015;17:1816–1822.
78. Brahimi A, Desai AS, Claggett B, Liu J, Hartley LH, Finn PV, Solomon SD, McMurray JJV, Packer M, Swedberg K, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. *Eur Heart J.* 2015;36:1990–1997.
79. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the dig trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. *Control Clin Trials.* 1996;17:77–97.
80. Boden E, Ziesche S, Carson PE, Conrad H, Cohn JN. Rationale and Design of the Third Vasodilator-Heart Failure Trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. *Am J Cardiol.* 1996;77:1078–1082.
81. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberger GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the praise trial. *Am J Cardiol.* 1998;82:881–887.
82. Bardy GH, Lee KL, Mark D, Poole J, Fishbein D. Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT). In: Woosley RL, Singh SN, eds. *Arrhythmia Treatment and Therapy: Evaluation of Clinical Trial Evidence.* New York, NY: Marcel Dekker; 2000:323–342.
83. Saxon LA, Boehmer JP, Hummel J, Kacet S, De Marco T, Naccarelli G, Daoud E. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. *Am J Cardiol.* 1999;83:120–123.
84. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION) trial. *J Card Fail.* 2000;6:276–285.
85. Remme WJ; CARMEN Steering Committee and Investigators. The Carvedilol and ACE-inhibitor Remodelling Mild Heart Failure EvaluationN trial (CARMEN)—rationale and design. *Cardiovasc Drugs Ther.* 2001;15:69–77.
86. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L; The CARE-HF study Steering

- Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and endpoints. *Eur J Heart Fail*. 2001;3:481–489.
87. Konstam MA, Poole-Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GAJ, et al. Design of the Heart failure endpoint evaluation of All-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. *Eur J Heart Fail*. 2008;10:899–906.
 88. Willenheimer R, Erdmann E, Follath F, Krum H, Ponikowski P, Silke B, van Veldhuisen DJ, van de Ven L, Verkenne P, Lechat P; on behalf of the CIBIS-III investigators. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. *Eur J Heart Fail*. 2004;6:493–500.
 89. Freudenberg RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, Colucci WS, Hare JM. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure. *Expert Opin Investig Drugs*. 2004;13:1509–1516.
 90. Torre-Amione G, Bourge RC, Colucci WS, Greenberg B, Pratt C, Rouleau J-L, Sestier F, Moyé LA, Geddes JA, Nemet AJ, et al. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. *Can J Cardiol*. 2007;23:369–376.
 91. Arya A, Block M, Kautzner J, Lewalter T, Mörtel H, Sack S, Schumacher B, Søgaard P, Taborsky M, Husser D, et al.; IN-TIME investigators. Influence of Home Monitoring on the clinical status of heart failure patients: design and rationale of the IN-TIME study. *Eur J Heart Fail*. 2008;10:1143–1148.
 92. Guha A, Dey AK, Armanious M, Dodd K, Bonsu J, Jneid H, Abraham W, Fradley MG, Addison D. Health care utilization and mortality associated with heart failure-related admissions among cancer patients. *ESC Heart Fail*. 2019;6:733–746.
 93. Yoshihisa A, Ichijo Y, Watanabe K, Sato Y, Kanno Y, Takiguchi M, Yokokawa T, Abe S, Misaka T, Sato T, et al. Prior history and incidence of cancer impacts on cardiac prognosis in hospitalized patients with heart failure. *Circ J Off J Jpn Circ Soc*. 2019;83:1709–1717.
 94. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, et al. Declining risk of sudden death in heart failure. *N Engl J Med*. 2017;377:41–51.
 95. Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer. *Circulation*. 2018;138:735–742.
 96. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer patients. *Eur Heart J*. 2019;40:3889–3897.
 97. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, López-Fernández T, Lainscak M, Pudil R, et al.; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. *Eur J Heart Fail*. 2018;20:879–887.
 98. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kiener LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, et al. Heart failure stimulates tumor growth by circulating factors. *Circulation*. 2018;138:678–691.
 99. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. *Cardiovasc Res*. 2019;115:844–853.
 100. Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghade M, Butler J. Mode of death in heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2017;69:556–569.
 101. Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, Wei L, Jneid H, Addison D. Representation of patients with cardiovascular disease in pivotal cancer clinical trials. *Circulation*. 2019;139:2594–2596.

SUPPLEMENTAL MATERIAL

Table S1. Risk of bias in HF_rEF RCTs with published cancer mortality.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data addressed (attrition bias)	Selective reporting (reporting bias)
CONSENSUS ¹³	Low	Low	Low	Low	Low	Low
V-HeFT ¹⁴	Low	Low	Low	Low	Low	Low
GESICA ¹⁵	Low	Low	High	High	Low	Low
CABG Patch ^{16,74}	Low	Low	High	Low	Low	Low
DEFINITE ¹⁷	Low	Low	High	Low	Low	Low
CHARM-Alt ^{18,75}	Low	Low	Low	Low	Low	Low
CHARM-Add ^{19,75}	Low	Low	Low	Low	Low	Low
AF-CHF ²⁰	Low	Low	High	Low	Low	Low
GISSI-HF ²¹	Low	Low	Low	Low	Low	Low
STICH ^{22,76}	Low	Low	High	Low	High	Low
CORONA ²³	Low	Low	Low	Low	Low	Low
REVERSE ²⁴	Low	Low	Low	Low	Low	Low
MADIT-CRT ^{25,77}	Low	Low	Low	Low	High	Low
ECHO-CRT ²⁶	Low	Low	Low	High	High	Low
PARADIGM-HF ^{27,78}	Low	Low	Low	Low	Low	Low

HF_rEF indicates heart failure with reduced left ventricular ejection fraction; RCTs, randomized controlled trials.

Table S2. Cancer mortality rates in HF_rEF RCTs and in the general population of the United States.

Trial name and period	Cancer mortality in the trial	Cancer mortality in the US population *	Cancer mortality in the US population of corresponding age **
	<i>n/100 pts/yr</i>	<i>n/100 pts/yr (year)</i>	<i>n/100 pts/yr (age range; year)</i>
CONSENSUS 1985-1986 ¹³	0	0.2 (1985)	<i>Not available</i>
V-HeFT II 1986-1990 ¹⁴	0.9	0.2 (1986)	0.5 (50-69 yrs; 1990)
GESICA 1989-1993 ¹⁵	0.4	0.2 (1989)	0.5 (50-69 yrs; 1990-1993)
CABG Patch 1993-1997 ^{16,74}	0.5	0.2 (1993)	0.4 (50-69 yrs; 1993-1997)
DEFINITE 1998-2003 ¹⁷	0.9	0.2 (1998)	0.4 (50-69 yrs; 1998-2003)
CHARM-Alternative 1999-2003 ^{18,75}	0.9	0.2 (1999)	0.4 (50-69 yrs; 1999-2003)
CHARM-Added 1999-2003 ^{19,75}	0.6	0.2 (1999)	0.4 (50-69 yrs; 1999-2003)
AF-CHF 2001-2007 ²⁰	0.8	0.2 (2001)	0.4 (50-69 yrs; 2001-2007)
GISSI-HF 2002-2008 ²¹	0.8	0.2 (2002)	0.3 (50-69 yrs; 2002-2008)
STICH 2002-2010 ^{22,76}	0.6	0.2 (2002)	0.3 (50-69 yrs; 2002-2010)
CORONA 2003-2007 ²³	0.8	0.2 (2003)	1.3 (>70 yrs; 2003-2007)
REVERSE 2004-2006 ²⁴	0.2	0.2 (2004)	0.3 (50-69 yrs; 2004-2006)
MADIT-CRT 2004-2008 ^{25,77}	0.3	0.2 (2004)	0.3 (50-69 yrs; 2004-2008)
ECHO-CRT 2008-2013 ²⁶	0.4	0.2 (2008)	0.3 (50-69 yrs; 2008-2013)
PARADIGM-HF 2009-2014 ^{27,78}	0.4	0.2 (2009)	0.3 (50-69 yrs; 2009-2014)

* source: https://seer.cancer.gov/archive/csr/1975_2015/

** source: <https://ourworldindata.org/cancer>, in which cancer mortality rates are provided per each calendar year stratified according to age (all ages, 50-69 years or >70 years). The values presented in the table are the mean of the mortality rates in the years when the RCT was performed, for the corresponding age group. For

example, PARADIGM-HF was conducted from 2009 to 2014, and the mean age of the participants was 63.8 years: thus, 0.3/100 pts/yr is the mean of the cancer mortality rates in the US population aged 50 to 69 years in 2009, 2010, 2011, 2012, 2013 and 2014.

HFrEF indicates heart failure with reduced left ventricular ejection fraction; RCTs, randomized controlled trials.

Table S3. Univariate meta-regression analysis.

	Coefficient (95% CI)*	P value
Cancer mortality		
Age, 1-year increase	-0.0017 (-0.0491 to 0.0456)	0.94
Male sex	-0.0038 (-0.0469 to 0.0393)	0.86
Ischemic etiology, 10-unit increase	0.0036 (-0.0084 to 0.0091)	0.94
Follow-up (years)	-0.0398 (-0.2775 to 0.1978)	0.74
DMD control	-0.1138 (-0.3861 to 0.1585)	0.41
DMD treatment	-0.1421 (-0.5335 to 0.2492)	0.48
CRT-D/ICD control (%)	-0.0152 (-0.0355 to 0.0052)	0.14
CRT-D/ICD treatment (%)	-0.0013 (-0.0128 to 0.0103)	0.83
CV mortality		
Age, 1-year increase	-0.0051 (-0.0349 to 0.0247)	0.74
Male sex	0.0013 (-0.0162 to 0.0188)	0.89
Ischemic etiology, 10-unit increase	0.0020 (-0.0027 to 0.0068)	0.40
Follow-up (years)	-0.0007 (-0.1254 to 0.1239)	0.99
DMD control	-0.0300 (-0.1731 to 0.1131)	0.68
DMD treatment	-0.0360 (-0.2318 to 0.1598)	0.72
CRT-D/ICD control (%)	0.0030 (-0.0015 to 0.0076)	0.19
CRT-D/ICD treatment (%)	0.0010 (-0.0024 to 0.0044)	0.57
Overall mortality		
Age, 1-year increase	-0.0033 (-0.0228 to 0.0162)	0.74
Male sex	0.0021 (-0.0113 to 0.0156)	0.76
Ischemic etiology, 10-unit increase	0.0005 (-0.0027 to 0.0037)	0.75
Follow-up (years)	0.0071 (-0.0757 to 0.0898)	0.87
DMD control	-0.0518 (-0.1261 to 0.0225)	0.17
DMD treatment	-0.0791 (-0.1756 to 0.0174)	0.11
CRT-D/ICD control (%)	0.0025 (-0.0006 to 0.0057)	0.12
CRT-D/ICD treatment (%)	0.0016 (-0.0007 to 0.0039)	0.18

DMD indicates number of disease-modifying drug classes in the background therapy; CRT-D, cardiac resynchronization therapy with defibrillator; ICD, implanted cardioverter defibrillator.

Table S4. HFrEF RCTs without published cancer mortality.

Trial name and period	N. (males) and age of pts	Follow-up Yrs	Tested therapy Background disease-modifying therapy	All-cause mortality N.	CV mortality N.	Non-CV mortality N.
V-HeFT I 1980-1985 ²⁸	642 58.3 yrs	2.3	<i>Prazosin vs hydralazine + isosorbide dinitrate vs placebo</i>	283	267	16
SOLVD-T 1986-1989 ²⁹	2569 61 yrs	3.4	None <i>Enalapril vs placebo</i>	962	860	102
SOLVD-P 1986-1991 ³⁰	4228 59.1 yrs	3.1	<i>Enalapril vs placebo</i> BB: 24% MRA*: 4%	647	563	84
PROMISE 1989-1990 ³¹	1088 63.7 yrs	0.5	<i>Milrinone vs placebo</i> ACEi: 100%	295	284	11
CIBIS-I 1989-1993 ³²	641 59.7 yrs	1.9	<i>Bisoprolol vs placebo</i> ACEi: 90%	120	99	7
CHF-STAT 1991-1994 ³³	674 66 yrs	3.8	<i>Amiodarone vs placebo</i> BB: 4% ACEi: 78%	274	163	45
DIG 1991-1995 ^{34,79}	6800 63.5 yrs	3.1	<i>Digoxin vs placebo</i> ACEi: 95%	2375	2020	355
V-HeFT III 1991-1995 ^{35,80}	450 63 yrs	1.5	<i>Felodipine vs placebo</i> ACEi: 97%	60	48	12

PRAISE I 1992-1994 ^{36,81}	1153 64.7 yrs	1.2	<i>Amlodipine vs placebo</i> ACEi: 99%	413	368	45
PRIME II 1992-1995 ³⁷	1906 64.7 yrs	1	<i>Ibopamine vs placebo</i> ACEi: 92%	425	386	32
AUST-NZ 1992-1995 ³⁸	415 67 yrs	1.5	<i>Carvedilol vs placebo</i> ACEi: 86%	46	38	8
ATLAS 1992-1997 ⁴⁰	3164 63.6 yrs	3.8	<i>Lisinopril low-dose vs high-dose</i> ACEi: 100%	1383	1224	146
USCP 1993-1995 ³⁹	1094 58 yrs	0.5	<i>Carvedilol vs placebo</i> ACEi: 95%	53	51	2
MACH-I 1994-1996 ⁴¹	2590 62.8 yrs	1.6	<i>Mibefradil vs placebo</i> ACEi: 99% BB: 16%	669	599	70
ELITE I 1994-1996 ⁴²	722 73.5 yrs	0.9	<i>Losartan vs captopril</i> BB: 59%	49	36	13
VEST 1995-1996 ⁴³	3833 63 yrs	0.8	<i>Vesnarinone vs placebo</i> ACEi: 90%	802	750	52
RALES 1995-1998 ⁴⁴	1663 65±12 yrs	2	<i>Spirolactone vs placebo</i> ACEi: 95% BB: 11%	670	565	70
CIBIS-II 1995-1998 ⁴⁵	2647 61 yrs	1.3	<i>Bisoprolol vs placebo</i> ACEi: 96%	384	280	51
BEST 1995-1999 ⁴⁶	2708 60 yrs	2.0	<i>Bucindolol vs placebo</i>	860	731	93

			ACEi: 98% MRA: 4%			
PRAISE II 1995-2000 ⁴⁷	1654 59 yrs	2.8	<i>Amlodipine vs placebo</i> ACEi: 100%	540	454	86
			<i>Carvedilol vs metoprolol</i>			
COMET 1996-2000 ⁴⁸	3029 62 yrs	4.8	ACEi: 93% ARB: 6% BB: 4% MRA: 11%	1112	972	140
			<i>Metoprolol vs placebo</i>			
MERIT-HF 1997-1998 ⁴⁹	3991 63.8 yrs	1	ACEi/ARB: 96% MRA: 8%	362	331	31
			<i>Losartan vs captopril</i>			
ELITE II 1997-1999 ⁵⁰	3152 71.5 yrs	1.5	BB: 22% MRA*:22%	530	429	101
			<i>Carvedilol vs placebo</i>			
COPERNICUS 1997-2000 ^{9,51}	2289 63.3 yrs	0.9	ACEi/ARB: 97% MRA: 19%	323	282	23
			<i>Valsartan vs placebo</i>			
Val-HeFT 1997-2000 ⁵²	5010 62.7 yrs	1.9	ACEi: 93% BB: 35%	979	763	124
			<i>Amiodarone vs ICD vs placebo</i>			
SCD-HeFT 1997-2003 ^{9,53,82}	2521 60.1 yrs	3.8	ACEi/ARB: 96% BB: 69% MRA*: 20%	666	484	122
			<i>Moxonidine vs placebo</i>			
MOXCON 1998-1999 ⁵⁴	1934 64.2 yrs	NA		86	80	6

			ACEi: 87% BB: 1% MRA: 7%			
			<i>CRT vs standard therapy</i>			
CONTAK-CD 1998-2000 ^{55,83}	490 66 yrs	0.5	ACEi/ARB: 88% BB: 47% ICD: 100%	109	60	21
			<i>CRT-D vs CRT-P vs standard therapy</i>			
COMPANION 2000-2002 ^{9,56,84}	1520 67 yrs	1.3	ACEi/ARB: 89% BB: 68% CRT: 80% ICD: 39%	313	251	46
			<i>Carvedilol vs enalapril vs carvedilol + enalapril</i>			
CARMEN 2000-2003 ^{57,85}	572 62.3 yrs	1.7	ACEi/ARB: 66% BB: 67% MRA: 13%	42	38	4
			<i>CRT vs standard therapy</i>			
CARE-HF 2001-2004 ^{58,86}	813 67 yrs	2.4	ACEi/ARB: 95% BB: 72% MRA: 56%	202	167	34
			<i>Losartan low dose vs high dose</i>			
HEAAL 2001-2009 ^{59,87}	3846 66 yrs	4.7	BB: 72% MRA: 38%	1300	926	374
			<i>Bisoprolol followed by enalapril vs opposite sequence</i>			
CIBIS-III 2002-2005 ^{9,60,88}	1010 72.4 yrs	1.3		138	107	27

MRA: 13%						
HHH 2002-2005 ⁶¹	461 60 yrs	1	<i>Home telemonitoring ± transmission of vital signs ± periodic monitoring of cardio-respiratory activity</i>	33	30	3
ACEi/ARB: 87% BB: 84%						
<i>Oxypurinol vs placebo</i>						
OPT-CHF 2003-2004 ^{62,89}	405 64.5 yrs	0.5	ACEi/ARB: 96% BB: 92% MRA: 35%	16	12	4
<i>Immuno-modulation therapy vs placebo</i>						
ACCLAIM 2003-2005 ^{63,90}	2426 64.3 yrs	0.8	ACEi/ARB: 94% BB: 87% MRA: 49%	245	202	43
<i>Sertraline vs placebo</i>						
SADHART-CHF 2003-2008 ⁶⁴	469 62.2 yrs	0.3	ACEi/ARB: 79% BB: 84% ICD: 19%	33	26	7
<i>Aerobic exercise training vs standard therapy</i>						
HF-ACTION 2003-2008 ⁶⁵	2331 59 yrs	2.5	ACEi/ARB: 94% BB: 95% CRT: 18% ICD: 40% MRA: 45%	387	274	113
RAFT 2003-2009 ⁶⁶	1798 66.2 yrs	3.3	<i>ICD vs CRT-D</i>	422	292	130

			ACEi/ARB: 97% BB: 90% MRA: 42%			
<i>Nesiritide vs placebo</i>						
FUSION-II 2004-2006 ⁶⁷	911 65 yrs	0.3	ACEi/ARB: 59% BB: 65% CRT: 24% ICD: 39% MRA: 37%	85	74	11
<i>Ivabradine vs placebo</i>						
SHIFT 2006-2010 ^{68,91}	6505 60.4 yrs	1.9	ACEi/ARB: 93% BB: 90% CRT: 1% ICD: 3% MRA: 60%	1055	940	115
<i>Eplerenone vs placebo</i>						
EMPHASIS-HF 2006-2010 ⁶⁹	2737 68.8 yrs	1.8	ACEi/ARB: 93% BB: 87% CRT: 9% ICD: 13% MRA: 50%	384	332	52
<i>Tele-monitoring vs standard therapy</i>						
IN-TIME 2007-2010 ^{70,92}	664 65.5 yrs	1	ACEi/ARB: 89% BB: 92% CRT: 41% ICD: 59%	37	29	8
<i>Remote telemedical management vs standard therapy</i>						
TIM-HF 2008-2009 ⁷¹	710 66.9 yrs	2.2		109	86	23

			ACEi/ARB: 95% BB: 93% CRT: 16% ICD: 46% MRA: 64%			
			<i>ICD vs standard therapy</i>			
DANISH 2008-2014 ⁷²	1116 64 yrs	5.6	ACEi/ARB: 97% BB: 92% CRT: 58% MRA: 58%	251	172	79
			<i>Primary care vs HF clinic</i>			
COACH-2 2012-2014 ⁷³	189 72 yrs	1	ACEi/ARB: 92% BB: 92% MRA: 48%	20	13	7

HFrEF indicates heart failure with reduced left ventricular ejection fraction; RCTs, randomized controlled trials; CV, cardiovascular; BB, beta blocker; MRA, mineral receptor antagonist; ACEi, angiotensin-converting enzyme inhibitor; ICD, implanted cardioverter defibrillator; ARB, angiotensin receptor blocker; CRT(-D), cardiac resynchronization therapy (and ICD).

* potassium-sparing diuretics, may have not been MRA

Table S5. Potential reasons for exclusion of patients with malignancy from HFREF RCTs without cancer mortality data available.

Exclusion criteria possibly regarding patients with cancer	
V-HeFT I 1980-1985 ²⁸	“Disease likely to limit 5 year survival”
SOLVD-T 1986-1989 ²⁹	“Any other disease that may substantially shorten survival”. 39,924 patients identified, 12% excluded because of cancer or other life-threatening disease
SOLVD-P 1986-1991 ³⁰	Same as SOLVD-P
PROMISE 1989-1990 ³¹	<i>Cancer not considered among exclusion criteria</i>
CIBIS-I 1989-1993 ³²	“Patients whose life expectancy was shortened by a severe illness such as malignant disease”
CHF-STAT 1991-1994 ³³	“Serious disease other than heart disease that was likely to be fatal within three years”
DIG 1991-1995 ^{34,79}	<i>Cancer not considered among exclusion criteria</i>
V-HeFT III 1991-1995 ^{35,80}	“Significant comorbidity which, in the investigator’s opinion, makes survival for the duration of the study unlikely or would otherwise interfere with adherence to the protocol”
PRAISE I 1992-1994 ^{36,81}	“Other significant comorbidity that made survival or compliance with the protocol unlikely”
PRIME II 1992-1995 ³⁷	<i>Cancer not considered among exclusion criteria</i>
AUST-NZ 1992-1995 ³⁸	“Any other life-threatening non-cardiac disease”
ATLAS 1992-1997 ⁴⁰	“Any non-cardiac disorder that could limit survival”
USCP 1993-1995 ³⁹	“Any condition other than heart failure that could limit exercise or survival”
MACH-I 1994-1996 ⁴¹	“Any clinically significant disease other than HF”
ELITE I 1994-1996 ⁴²	“Unlikely survival for length of study or risk to patient”
VEST 1995-1996 ⁴³	“Cancer likely to limit life expectancy”

RALES 1995-1998 ⁴⁴	“Active cancer”
CIBIS-II 1995-1998 ⁴⁵	<i>Cancer not considered among exclusion criteria</i>
BEST 1995-1999 ⁴⁶	“Life expectancy of less than 3 years (..) or if they had hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that could adversely affect the safety or the efficacy of the study drug”
PRAISE II 1995-2000 ⁴⁷	“Any disease (other than heart failure) that might have limited survival”
COMET 1996-2000 ⁴⁸	“Any other serious systemic disease that might complicate management and reduce life expectancy”
MERIT-HF 1997-1998 ⁴⁹	“Any other serious disease that might complicate management and follow-up according to the protocol”
ELITE II 1997-1999 ⁵⁰	<i>Cancer not considered among exclusion criteria</i>
COPERNICUS 1997-2000 ^{9,51}	“Severe primary pulmonary, renal, or hepatic disease”
Val-HeFT 1997-2000 ⁵²	“Malignancies likely to limit 5-year survival”
SCD-HeFT 1997-2003 ^{9,53,82}	No information available
MOXCON 1998-1999 ⁵⁴	“Severe concomitant disease likely to reduce life expectancy to less than 5 years”
CONTAK-CD 1998-2000 ^{55,83}	“Life expectancy <6 months due to other medical conditions”
COMPANION 2000-2002 ^{9,56,84}	“Life expectancy <6 months because of any other medical conditions”
CARMEN 2000-2003 ^{57,85}	<i>Cancer not considered among exclusion criteria</i>
CARE-HF 2001-2004 ^{58,86}	“Life expectancy <1 year for disease unrelated to heart failure”
HEAAL 2001-2009 ^{59,87}	“Life-limiting disease other than heart failure”
CIBIS-III 2002-2005 ^{9,60,88}	“Significant disease, which in the investigator’s opinion would exclude the patient from the study”
HHH 2002-2005 ⁶¹	<i>Cancer not considered among exclusion criteria</i>

OPT-CHF 2003-2004 ^{62,89}	<i>Cancer not considered among exclusion criteria</i>
ACCLAIM 2003-2005 ^{63,90}	“Malignancy: evidence of disease within the previous five years. Exceptions: basal cell carcinoma, provided it was neither infiltrating nor sclerosing, or carcinoma in situ of the cervix”
SADHART-CHF 2003-2008 ⁶⁴	“Life-threatening comorbidity (estimated 50% mortality within 1 year)”
HF-ACTION 2003-2008 ⁶⁵	“Comorbid disease or behavioral or other limitations that interfere with performing exercise training or prevent the completion of 1 y of exercise training”
RAFT 2003-2009 ⁶⁶	“Major coexisting illness”
FUSION-II 2004-2006 ⁶⁷	<i>Cancer not considered among exclusion criteria</i>
SHIFT 2006-2010 ^{68,91}	<i>Cancer not considered among exclusion criteria</i>
EMPHASIS-HF 2006-2010 ⁶⁹	“Any other clinically significant, coexisting condition”
IN-TIME 2007-2010 ^{70,92}	<i>Cancer not considered among exclusion criteria</i>
TIM-HF 2008-2009 ⁷¹	“Any disease (HF excluded) reducing life expectancy to less than 1 year”
DANISH 2008-2014 ⁷²	“Receiving or having received cytotoxic or cytostatic chemotherapy and/or radiation therapy for treatment of a malignancy within 6 month before randomization or clinical evidence of current malignancy”
COACH-2 2012-2014 ⁷³	“The patient had a life expectancy < 6 months”

HFrEF indicates heart failure with reduced left ventricular ejection fraction; RCTs, randomized controlled trials; HF, heart failure.